Denali Therapeutics announced that the U.S. Food and Drug Administration granted accelerated approval for its enzyme replacement therapy AVLAYAH (tividenofusp alfa‑eknm) on March 25 2026. The approval marks the first FDA‑approved biologic capable of crossing the blood‑brain barrier to treat the neurological manifestations of Hunter syndrome (mucopolysaccharidosis type II).
AVLAYAH combines the deficient enzyme iduronate‑2‑sulfatase with Denali’s proprietary Transport Vehicle platform, enabling intravenous delivery to both peripheral tissues and the brain. The platform uses receptor‑mediated transcytosis to ferry the enzyme across the blood‑brain barrier, a capability that has not been achieved by any other approved therapy for this indication.
Clinical data supporting the approval showed a 91% reduction in cerebrospinal fluid heparan sulfate levels in a Phase 1/2 study, with 93% of treated patients achieving biomarker levels within the normal range by week 24. A global Phase 2/3 COMPASS trial is underway to confirm clinical benefit and support future worldwide regulatory submissions, ensuring that the surrogate endpoint translates into meaningful neurological improvement.
The approval represents Denali’s first commercial product and validates its Transport Vehicle platform, positioning the company to capture a significant share of the Hunter syndrome market. With a strong cash position and no debt, Denali has the financial flexibility to launch AVLAYAH, scale manufacturing, and pursue additional indications that could leverage the same delivery technology. The approval also gives Denali a first‑mover advantage, as the only other therapy, Elaprase, cannot cross the blood‑brain barrier and therefore does not address neurological symptoms. The recent rejection of a competing gene‑therapy candidate from REGENXBIO further strengthens Denali’s competitive position.
Ryan Watts, Chief Executive Officer, said the approval “marks a new era for the Hunter syndrome community as we deliver the first FDA‑approved therapy designed to cross the brain’s protective barrier for individuals and families living with this debilitating disease. This milestone validates our Transport Vehicle platform and its potential to overcome the limitations of existing treatments.”
The approval is expected to drive significant revenue growth for Denali, with analysts projecting that the launch of AVLAYAH will unlock a new revenue stream and support the company’s broader pipeline. The company’s strong cash position and validated technology platform provide a solid foundation for future product development and commercialization efforts.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.